The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Axitinib inhibition of [18F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): Implications for cytotoxic chemotherapy combinations.
C. Hoh
Consultant or Advisory Role - Pfizer (U)
Research Funding - Pfizer
J. R. Infante
No relevant relationships to disclose
H. A. Burris
No relevant relationships to disclose
J. C. Tarazi
Employment or Leadership Position - Pfizer
S. Kim
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
B. Rosbrook
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
T. R. Reid
No relevant relationships to disclose